Neumora Therapeutics (NMRA) Interest & Investment Income (2022 - 2026)

Neumora Therapeutics has reported Interest & Investment Income for 5 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 59.95% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (down 63.56% YoY), and the FY2025 full-year result was $8.3 million, down 58.14% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $1.2 million, down from $1.3 million in the prior quarter.
• The five-year high for Interest & Investment Income was $6.4 million in Q1 2024, with the low at $1.2 million in Q1 2026.
• Average Interest & Investment Income over 5 years is $3.3 million, with a median of $3.6 million recorded in 2023.
• Year-over-year, Interest & Investment Income soared 172.97% in 2023 and slumped 67.34% in 2025.
• Tracing NMRA's Interest & Investment Income over 5 years: stood at $2.3 million in 2022, then soared by 147.09% to $5.6 million in 2023, then fell by 27.59% to $4.1 million in 2024, then tumbled by 67.34% to $1.3 million in 2025, then dropped by 7.79% to $1.2 million in 2026.
• The last three Interest & Investment Income figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.

Peer Comparison